Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer
Background: Several recent studies have demonstrated that microRNAs (miRNAs) are stably detectable in plasma/serum. We tested miR-221 and miR-375, which are frequently reported to be highly and poorly expressed in pancreatic cancer (PCa), as candidates for plasma biomarkers in PCa. Methods: This stu...
Gespeichert in:
| Veröffentlicht in: | British journal of cancer 2013-02, Vol.108 (2), p.361-369 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 369 |
|---|---|
| container_issue | 2 |
| container_start_page | 361 |
| container_title | British journal of cancer |
| container_volume | 108 |
| creator | Kawaguchi, T Komatsu, S Ichikawa, D Morimura, R Tsujiura, M Konishi, H Takeshita, H Nagata, H Arita, T Hirajima, S Shiozaki, A Ikoma, H Okamoto, K Ochiai, T Taniguchi, H Otsuji, E |
| description | Background:
Several recent studies have demonstrated that microRNAs (miRNAs) are stably detectable in plasma/serum. We tested miR-221 and miR-375, which are frequently reported to be highly and poorly expressed in pancreatic cancer (PCa), as candidates for plasma biomarkers in PCa.
Methods:
This study was divided into three parts: (1) Confirmation of higher miR-221 levels in primary PCa tissue and cell lines than normal pancreatic tissues. (2) Evaluation of plasma miR-221 and miR-375 concentrations by comparing results from 47 consecutive PCa patients and 30 healthy volunteers. (3) Evaluation of the assay for monitoring tumour dynamics in PCa patients.
Results:
(1) Expression of miR-221 was significantly higher in PCa tissues and cell lines than normal pancreatic tissues. (2) Plasma miR-221 concentrations were significantly higher in PCa patients than that in benign pancreatic tumours (
P
=0.016) and controls (
P |
| doi_str_mv | 10.1038/bjc.2012.546 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3566805</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2884047711</sourcerecordid><originalsourceid>FETCH-LOGICAL-c563t-f9d518d3f929b81dbb6b7de6aeb96d82470b042d3bde16746c086a58cd4ab8b93</originalsourceid><addsrcrecordid>eNptkUtr3DAUhUVpaKZJdl0XQwl0UU_1sGR5UyhDH4FAoU3WQi9PNNiyK9kN_fe9ZiavkpV0dT7uPVcHoTcErwlm8qPZ2TXFhK55JV6gFeGMlkTS-iVaYYzrEjcUH6PXOe-gbLCsX6FjyhhtKOMr9GvThRis7orQj9pOxdAWNiQ7d3oKcVv04WdJKSlCLMZO514vwAiaj1MubsN0A1W0ycOTLSxcfTpFR63usj87nCfo-uuXq8338vLHt4vN58vScsGmsm0cJ9KxtqGNkcQZI0ztvNDeNMJJWtXY4Io6Zpwnoq6ExVJoLq2rtJGmYSfo077vOJveOwuWku7UmEKv01816KCeKjHcqO3wRzEuhMQcGrw_NEjD79nnSfUhW991OvphzopQybEkUi6z3v2H7oY5RVhvoSpWY8oZUB_2lE1Dzsm392YIVktaCtJSS1oK0gL87eMF7uG7eAA4PwA6Q0Ztgv8N-YGrCa4EJcCVey6DFLc-PXL33OB_dIir7g</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1284370253</pqid></control><display><type>article</type><title>Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Nature Journals Online</source><source>PubMed Central</source><source>SpringerLink Journals - AutoHoldings</source><creator>Kawaguchi, T ; Komatsu, S ; Ichikawa, D ; Morimura, R ; Tsujiura, M ; Konishi, H ; Takeshita, H ; Nagata, H ; Arita, T ; Hirajima, S ; Shiozaki, A ; Ikoma, H ; Okamoto, K ; Ochiai, T ; Taniguchi, H ; Otsuji, E</creator><creatorcontrib>Kawaguchi, T ; Komatsu, S ; Ichikawa, D ; Morimura, R ; Tsujiura, M ; Konishi, H ; Takeshita, H ; Nagata, H ; Arita, T ; Hirajima, S ; Shiozaki, A ; Ikoma, H ; Okamoto, K ; Ochiai, T ; Taniguchi, H ; Otsuji, E</creatorcontrib><description>Background:
Several recent studies have demonstrated that microRNAs (miRNAs) are stably detectable in plasma/serum. We tested miR-221 and miR-375, which are frequently reported to be highly and poorly expressed in pancreatic cancer (PCa), as candidates for plasma biomarkers in PCa.
Methods:
This study was divided into three parts: (1) Confirmation of higher miR-221 levels in primary PCa tissue and cell lines than normal pancreatic tissues. (2) Evaluation of plasma miR-221 and miR-375 concentrations by comparing results from 47 consecutive PCa patients and 30 healthy volunteers. (3) Evaluation of the assay for monitoring tumour dynamics in PCa patients.
Results:
(1) Expression of miR-221 was significantly higher in PCa tissues and cell lines than normal pancreatic tissues. (2) Plasma miR-221 concentrations were significantly higher in PCa patients than that in benign pancreatic tumours (
P
=0.016) and controls (
P
<0.0005), while plasma miR-375 concentrations tended to be lower in PCa patients (
P
=0.064), and the miR-221/miR-375 ratio was significantly higher (
P
<0.0001) in PCa patients than in controls. (3) Plasma miR-221 concentrations were significantly reduced in postoperative samples (
P
=0.018). Furthermore, PCa patients with high plasma miR-221 concentrations had significant correlation with distant metastasis (
P
=0.041), and non-resectable status (
P
=0.021).
Conclusion:
Plasma miR-221 could be a useful biomarker for cancer detection, monitoring tumour dynamics and predicting malignant outcomes in PCa patients, and may contribute to clinical decision making in PCa treatments.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/bjc.2012.546</identifier><identifier>PMID: 23329235</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/337/384/331 ; 692/699/67/1504/1713 ; 692/699/67/1857 ; 692/700/139 ; Aged ; Biological and medical sciences ; Biomarkers, Tumor - blood ; Biomarkers, Tumor - genetics ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Cell Line, Tumor ; Drug Resistance ; Epidemiology ; Female ; Gastroenterology. Liver. Pancreas. Abdomen ; Humans ; Liver. Biliary tract. Portal circulation. Exocrine pancreas ; Male ; Medical sciences ; MicroRNAs - blood ; Molecular Diagnostics ; Molecular Medicine ; Oncology ; Pancreatic cancer ; Pancreatic Neoplasms - blood ; Pancreatic Neoplasms - genetics ; Tumors</subject><ispartof>British journal of cancer, 2013-02, Vol.108 (2), p.361-369</ispartof><rights>The Author(s) 2013</rights><rights>2014 INIST-CNRS</rights><rights>Copyright Nature Publishing Group Feb 5, 2013</rights><rights>Copyright © 2013 Cancer Research UK 2013 Cancer Research UK</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c563t-f9d518d3f929b81dbb6b7de6aeb96d82470b042d3bde16746c086a58cd4ab8b93</citedby><cites>FETCH-LOGICAL-c563t-f9d518d3f929b81dbb6b7de6aeb96d82470b042d3bde16746c086a58cd4ab8b93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3566805/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3566805/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,41488,42557,51319,53791,53793</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27104621$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23329235$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kawaguchi, T</creatorcontrib><creatorcontrib>Komatsu, S</creatorcontrib><creatorcontrib>Ichikawa, D</creatorcontrib><creatorcontrib>Morimura, R</creatorcontrib><creatorcontrib>Tsujiura, M</creatorcontrib><creatorcontrib>Konishi, H</creatorcontrib><creatorcontrib>Takeshita, H</creatorcontrib><creatorcontrib>Nagata, H</creatorcontrib><creatorcontrib>Arita, T</creatorcontrib><creatorcontrib>Hirajima, S</creatorcontrib><creatorcontrib>Shiozaki, A</creatorcontrib><creatorcontrib>Ikoma, H</creatorcontrib><creatorcontrib>Okamoto, K</creatorcontrib><creatorcontrib>Ochiai, T</creatorcontrib><creatorcontrib>Taniguchi, H</creatorcontrib><creatorcontrib>Otsuji, E</creatorcontrib><title>Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>Background:
Several recent studies have demonstrated that microRNAs (miRNAs) are stably detectable in plasma/serum. We tested miR-221 and miR-375, which are frequently reported to be highly and poorly expressed in pancreatic cancer (PCa), as candidates for plasma biomarkers in PCa.
Methods:
This study was divided into three parts: (1) Confirmation of higher miR-221 levels in primary PCa tissue and cell lines than normal pancreatic tissues. (2) Evaluation of plasma miR-221 and miR-375 concentrations by comparing results from 47 consecutive PCa patients and 30 healthy volunteers. (3) Evaluation of the assay for monitoring tumour dynamics in PCa patients.
Results:
(1) Expression of miR-221 was significantly higher in PCa tissues and cell lines than normal pancreatic tissues. (2) Plasma miR-221 concentrations were significantly higher in PCa patients than that in benign pancreatic tumours (
P
=0.016) and controls (
P
<0.0005), while plasma miR-375 concentrations tended to be lower in PCa patients (
P
=0.064), and the miR-221/miR-375 ratio was significantly higher (
P
<0.0001) in PCa patients than in controls. (3) Plasma miR-221 concentrations were significantly reduced in postoperative samples (
P
=0.018). Furthermore, PCa patients with high plasma miR-221 concentrations had significant correlation with distant metastasis (
P
=0.041), and non-resectable status (
P
=0.021).
Conclusion:
Plasma miR-221 could be a useful biomarker for cancer detection, monitoring tumour dynamics and predicting malignant outcomes in PCa patients, and may contribute to clinical decision making in PCa treatments.</description><subject>631/337/384/331</subject><subject>692/699/67/1504/1713</subject><subject>692/699/67/1857</subject><subject>692/700/139</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - blood</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Cell Line, Tumor</subject><subject>Drug Resistance</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Humans</subject><subject>Liver. Biliary tract. Portal circulation. Exocrine pancreas</subject><subject>Male</subject><subject>Medical sciences</subject><subject>MicroRNAs - blood</subject><subject>Molecular Diagnostics</subject><subject>Molecular Medicine</subject><subject>Oncology</subject><subject>Pancreatic cancer</subject><subject>Pancreatic Neoplasms - blood</subject><subject>Pancreatic Neoplasms - genetics</subject><subject>Tumors</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNptkUtr3DAUhUVpaKZJdl0XQwl0UU_1sGR5UyhDH4FAoU3WQi9PNNiyK9kN_fe9ZiavkpV0dT7uPVcHoTcErwlm8qPZ2TXFhK55JV6gFeGMlkTS-iVaYYzrEjcUH6PXOe-gbLCsX6FjyhhtKOMr9GvThRis7orQj9pOxdAWNiQ7d3oKcVv04WdJKSlCLMZO514vwAiaj1MubsN0A1W0ycOTLSxcfTpFR63usj87nCfo-uuXq8338vLHt4vN58vScsGmsm0cJ9KxtqGNkcQZI0ztvNDeNMJJWtXY4Io6Zpwnoq6ExVJoLq2rtJGmYSfo077vOJveOwuWku7UmEKv01816KCeKjHcqO3wRzEuhMQcGrw_NEjD79nnSfUhW991OvphzopQybEkUi6z3v2H7oY5RVhvoSpWY8oZUB_2lE1Dzsm392YIVktaCtJSS1oK0gL87eMF7uG7eAA4PwA6Q0Ztgv8N-YGrCa4EJcCVey6DFLc-PXL33OB_dIir7g</recordid><startdate>20130205</startdate><enddate>20130205</enddate><creator>Kawaguchi, T</creator><creator>Komatsu, S</creator><creator>Ichikawa, D</creator><creator>Morimura, R</creator><creator>Tsujiura, M</creator><creator>Konishi, H</creator><creator>Takeshita, H</creator><creator>Nagata, H</creator><creator>Arita, T</creator><creator>Hirajima, S</creator><creator>Shiozaki, A</creator><creator>Ikoma, H</creator><creator>Okamoto, K</creator><creator>Ochiai, T</creator><creator>Taniguchi, H</creator><creator>Otsuji, E</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20130205</creationdate><title>Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer</title><author>Kawaguchi, T ; Komatsu, S ; Ichikawa, D ; Morimura, R ; Tsujiura, M ; Konishi, H ; Takeshita, H ; Nagata, H ; Arita, T ; Hirajima, S ; Shiozaki, A ; Ikoma, H ; Okamoto, K ; Ochiai, T ; Taniguchi, H ; Otsuji, E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c563t-f9d518d3f929b81dbb6b7de6aeb96d82470b042d3bde16746c086a58cd4ab8b93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>631/337/384/331</topic><topic>692/699/67/1504/1713</topic><topic>692/699/67/1857</topic><topic>692/700/139</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - blood</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Cell Line, Tumor</topic><topic>Drug Resistance</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Humans</topic><topic>Liver. Biliary tract. Portal circulation. Exocrine pancreas</topic><topic>Male</topic><topic>Medical sciences</topic><topic>MicroRNAs - blood</topic><topic>Molecular Diagnostics</topic><topic>Molecular Medicine</topic><topic>Oncology</topic><topic>Pancreatic cancer</topic><topic>Pancreatic Neoplasms - blood</topic><topic>Pancreatic Neoplasms - genetics</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kawaguchi, T</creatorcontrib><creatorcontrib>Komatsu, S</creatorcontrib><creatorcontrib>Ichikawa, D</creatorcontrib><creatorcontrib>Morimura, R</creatorcontrib><creatorcontrib>Tsujiura, M</creatorcontrib><creatorcontrib>Konishi, H</creatorcontrib><creatorcontrib>Takeshita, H</creatorcontrib><creatorcontrib>Nagata, H</creatorcontrib><creatorcontrib>Arita, T</creatorcontrib><creatorcontrib>Hirajima, S</creatorcontrib><creatorcontrib>Shiozaki, A</creatorcontrib><creatorcontrib>Ikoma, H</creatorcontrib><creatorcontrib>Okamoto, K</creatorcontrib><creatorcontrib>Ochiai, T</creatorcontrib><creatorcontrib>Taniguchi, H</creatorcontrib><creatorcontrib>Otsuji, E</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kawaguchi, T</au><au>Komatsu, S</au><au>Ichikawa, D</au><au>Morimura, R</au><au>Tsujiura, M</au><au>Konishi, H</au><au>Takeshita, H</au><au>Nagata, H</au><au>Arita, T</au><au>Hirajima, S</au><au>Shiozaki, A</au><au>Ikoma, H</au><au>Okamoto, K</au><au>Ochiai, T</au><au>Taniguchi, H</au><au>Otsuji, E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>2013-02-05</date><risdate>2013</risdate><volume>108</volume><issue>2</issue><spage>361</spage><epage>369</epage><pages>361-369</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>Background:
Several recent studies have demonstrated that microRNAs (miRNAs) are stably detectable in plasma/serum. We tested miR-221 and miR-375, which are frequently reported to be highly and poorly expressed in pancreatic cancer (PCa), as candidates for plasma biomarkers in PCa.
Methods:
This study was divided into three parts: (1) Confirmation of higher miR-221 levels in primary PCa tissue and cell lines than normal pancreatic tissues. (2) Evaluation of plasma miR-221 and miR-375 concentrations by comparing results from 47 consecutive PCa patients and 30 healthy volunteers. (3) Evaluation of the assay for monitoring tumour dynamics in PCa patients.
Results:
(1) Expression of miR-221 was significantly higher in PCa tissues and cell lines than normal pancreatic tissues. (2) Plasma miR-221 concentrations were significantly higher in PCa patients than that in benign pancreatic tumours (
P
=0.016) and controls (
P
<0.0005), while plasma miR-375 concentrations tended to be lower in PCa patients (
P
=0.064), and the miR-221/miR-375 ratio was significantly higher (
P
<0.0001) in PCa patients than in controls. (3) Plasma miR-221 concentrations were significantly reduced in postoperative samples (
P
=0.018). Furthermore, PCa patients with high plasma miR-221 concentrations had significant correlation with distant metastasis (
P
=0.041), and non-resectable status (
P
=0.021).
Conclusion:
Plasma miR-221 could be a useful biomarker for cancer detection, monitoring tumour dynamics and predicting malignant outcomes in PCa patients, and may contribute to clinical decision making in PCa treatments.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>23329235</pmid><doi>10.1038/bjc.2012.546</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0920 |
| ispartof | British journal of cancer, 2013-02, Vol.108 (2), p.361-369 |
| issn | 0007-0920 1532-1827 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3566805 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Nature Journals Online; PubMed Central; SpringerLink Journals - AutoHoldings |
| subjects | 631/337/384/331 692/699/67/1504/1713 692/699/67/1857 692/700/139 Aged Biological and medical sciences Biomarkers, Tumor - blood Biomarkers, Tumor - genetics Biomedical and Life Sciences Biomedicine Cancer Research Cell Line, Tumor Drug Resistance Epidemiology Female Gastroenterology. Liver. Pancreas. Abdomen Humans Liver. Biliary tract. Portal circulation. Exocrine pancreas Male Medical sciences MicroRNAs - blood Molecular Diagnostics Molecular Medicine Oncology Pancreatic cancer Pancreatic Neoplasms - blood Pancreatic Neoplasms - genetics Tumors |
| title | Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T22%3A40%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20impact%20of%20circulating%20miR-221%20in%20plasma%20of%20patients%20with%20pancreatic%20cancer&rft.jtitle=British%20journal%20of%20cancer&rft.au=Kawaguchi,%20T&rft.date=2013-02-05&rft.volume=108&rft.issue=2&rft.spage=361&rft.epage=369&rft.pages=361-369&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1038/bjc.2012.546&rft_dat=%3Cproquest_pubme%3E2884047711%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1284370253&rft_id=info:pmid/23329235&rfr_iscdi=true |